NCT07024797View on ClinicalTrials.gov

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Healthy Volunteer
Interventions
DRUG

ABBV-932

Oral Capsule

DRUG

Placebo for ABBV-932

Oral Capsule

Trial Locations (1)

200030

RECRUITING

Shanghai Mental Health Center /ID# 273427, Shanghai

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY